Sermorelin Acetate (GHRH 1-29) | ≥99% Purity

Research Use Only (RUO) | USA Cold-Chain Stored

Sermorelin Acetate is a high-purity synthetic peptide and the primary compliant Growth Hormone-Releasing Hormone (GHRH) agonist for investigating pituitary pulsatility, sleep architecture, and neuroendocrine function.

Sermorelin Acetate (GHRH 1-29) 2D Structure. Source: MedKoo Biosciences

Product Specifications

Chemical Identity & "Survivor" Status

Sermorelin (GRF 1-29) is a synthetic polypeptide comprising the first 29 amino acids of endogenous human GHRH. Unlike newer synthetic peptides that have faced regulatory bans, it possesses a unique "Safe Harbor" status in the USA.

• Structural Efficiency: It contains the full biological activity of GHRH within the N-terminal 29-amino acid sequence, making it highly specific to the GHRH receptor.

• Regulatory Resilience: Because it is the active pharmaceutical ingredient of a formerly FDA-approved drug (Geref) that was not withdrawn for safety reasons, it remains the "Last Peptide Standing" for compliant research into the somatotropic axis.

• Preservation of Physiology: Unlike exogenous hormones, Sermorelin stimulates the anterior pituitary to secrete growth hormone in a natural, pulsatile manner. It works with the body’s natural feedback loops—specifically the inhibitory control of somatostatin.

The Physiological Advantage

Research Context & Clinical Insights (2025–2026)

Sleep Architecture (Deep Sleep)

Research indicates Sermorelin acts as a neurotransmitter to promote Slow-Wave Sleep (SWS), the restorative stage where endogenous recovery peaks. This makes it a critical tool for studying age-related sleep decline.

Body Composition & Visceral Fat

By restoring GH pulsatility, Sermorelin reactivates lipolytic (fat-breaking) machinery in visceral fat depots. Studies in aging models have shown increases in lean body mass (+1.4 kg in men) and improvements in skin thickness and collagen density.

The "Stacking" Shift

With Ipamorelin now placed in FDA Category 2 (restricted), researchers are shifting focus to Sermorelin Monotherapy. It remains the primary legal tool for stimulating the somatotropic axis in the USA.

Why Researchers Source from Profound Aminos

• The "Grey Market" Antidote: While many vendors sell undefined "research chemicals," our Sermorelin is strictly tested to confirm it is not a salt-heavy synthesis byproduct. We ensure <1.0 EU/mg endotoxin levels for safe cellular assays.

• USA-Based Cold-Chain: Peptides are fragile. We store our inventory at -20°C in the USA to prevent degradation of the amino acid sequence before it reaches your lab.

• Verified Sequence: Our Certificates of Analysis (COA) confirm the 1-29 fragment identity, ensuring you are researching the specific biologically active motif.

Frequently Asked Questions

Why is Sermorelin considered the "safest" GHRH analogue for research?

Unlike rhGH, which can cause overdose and shutdown of the pituitary gland, Sermorelin is self-limiting. It remains subject to the body’s Somatostatin negative feedback loop. If GH levels get too high, the body naturally blocks the effect of Sermorelin, making overdose virtually impossible in research models.

How does Sermorelin compare to trending peptides like Reta or Sema?

They target completely different systems. Reta and Sema are incretin mimetics focused on insulin sensitivity and appetite suppression for obesity and Type 2 Diabetes. Sermorelin focuses on the Neuroendocrine Axis—specifically repairing the pulsatile secretion of Growth Hormone for tissue repair, sleep optimization, and anti-aging modeling.

Why is this peptide preferred over Ipamorelin in 2026?

Regulatory necessity. In late 2023/2024, the FDA moved Ipamorelin to Category 2, effectively restricting its compliant compounding use. Sermorelin was not restricted because it was previously an FDA-approved drug with a proven safety record, making it the "Gold Standard" for legally compliant research.

Does Sermorelin show immediate effects in metabolic studies?

Unlike the rapid weight loss seen with Tirzepatide, Sermorelin’s effects are cumulative. Research shows significant elevation of IGF-1 levels typically occurs within 4 to 12 weeks of nightly administration in study protocols.

Regulatory & Compliance Statement

Classification: Research Use Only (RUO) Peptide.

Compliance: Sermorelin acetate is listed as a compliant bulk drug substance for 503A compounding under the FD&C Act, as the API of a formerly approved drug (Geref).

Usage: Strictly for Laboratory Research Use Only. Not for human consumption, diagnostic, or clinical procedures.